Abi Vainstein

Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers

Michal Abraham, Yaron Pereg, Baruch Bulvik et al. · Clinical Cancer Research · 2017 · 53 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

GENESIS: Phase III Trial Evaluating BL-8040 + G-CSF to Mobilize Hematopoietic Cells for Autologous Transplant in Myeloma

Zachary Crees, Keith Stockerl‐Goldstein, Abi Vainstein et al. · Future Oncology · 2019 · 25 citations · Full text

Medicine, Hematology, Immunology +17

The Peptidic CXCR4 Antagonist, BL-8040, Significantly Reduces Bone Marrow Immature Leukemia Progenitors By Inducing Differentiation, Apoptosis and Mobilization: Results of the Dose Escalation Clinical Trial in Acute Myeloid Leukemia

Gautam Borthakur, Yishai Ofran, Arnon Nagler et al. · Blood · 2015 · 17 citations

Medicine, Oncology, Pharmacology +15

AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models

Stephen M. Shaw, Jenny Middleton, Kim Wigglesworth et al. · Cancer Cell International · 2019 · 17 citations · Full text

Life Sciences, Immunology, Oncology +17

A Multi-Center Phase IIA Trial to Assess the Safety and Efficacy of BL-8040 (a CXCR4 Inhibitor) in Combination with Pembrolizumab and Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma (PDAC)

Manuel Hidalgo, Valerya Semenisty, Bruno Bockorny et al. · Annals of Oncology · 2019 · 14 citations

Medicine, Oncology, Pharmacology +15